Evidence map›Paper›PMID 38847928›Full record

Observational studyEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2024

Clinical manifestations and biomarkers to predict mortality risk in adults with invasive Streptococcus dysgalactiae subsp. equisimilis infections.

Shigeo Hanada, Takeaki Wajima, Misako Takata, Miyuki Morozumi, Michi Shoji, Satoshi Iwata, Kimiko Ubukata

Abstract readMulticenter StudyObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Clinical and Molecular Characteristics ofOpen forum infectious diseases · 2026
    Article
  2. Observational
  3. Genomic and patient epidemiology ofMicrobiology spectrum · 2026
    Article
  4. Analysis ofmBio · 2025
    Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Shigeo Hanada *Department of Respiratory Medicine, Respiratory Center, Toranomon Hospital, 2-2-2 Toranomon, Minato-ku, Tokyo, 105-8470, Japan. gourouhanada@yahoo.co.jp.
Takeaki WajimaDepartment of Microbiology, Faculty of Pharmacy, Meijo University, Nagoya, Japan.
Misako TakataDepartment of Microbiology, Tokyo Medical University, Tokyo, Japan.
Miyuki MorozumiDepartment of Microbiology, Tokyo Medical University, Tokyo, Japan.
Michi ShojiDepartment of Infectious Disease, National Sanatorium Tamazenshoen, Tokyo, Japan.
Satoshi IwataDepartment of Microbiology, Tokyo Medical University, Tokyo, Japan.
Kimiko Ubukata *Department of Microbiology, Tokyo Medical University, Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe incidence of invasive Streptococcus dysgalactiae subsp. equisimilis (iSDSE) infections is increasing in developed countries, but studies on the risk factors for death in iSDSE infections are scant. Here, we aimed to clarify risk factors and predictors of mortality in adults with iSDSE infections.

methodsA multicentre observational study of adults with iSDSE infections was conducted to investigate the effects of host factors, disease severity, biomarkers, and antibiotic regimens, and bacterial factors on 28-day mortality.

resultsThe overall mortality rate of 588 patients was 10.4%, with a significant increase in those aged ≥ 60 years. Most of the patients (97.4%) had underlying diseases. The mortality rate (70.4%) of patients with severe disease was significantly higher than that of patients with mild-to-moderate disease (4.3%; p < 0.001). The risk factors for death identified using multivariable analysis were age ≥ 60 years (hazard ratio [HR], 3.4; 95% confidence interval [CI], 1.0-11.3, p = 0.042); severe disease (HR, 15.0; 95% CI 7.7-29.2, p < 0.001); bacteraemia without primary focus (HR, 20.5; 95% CI 2.8-152.3, p = 0.003); serum creatinine ≥ 2.0 mg/dL (HR, 2.2; 95% CI 1.2-4.0, p = 0.010); serum creatine kinase ≥ 300 IU/L (HR, 2.1; 95% CI 1.1-3.8, p = 0.019); and macrolide resistance (HR, 1.8; 95% CI 1.0-3.3, p = 0.048). Treatment regimens and emm types were not associated with poor outcomes.

conclusionEvaluation of clinical manifestations and biomarkers on admission is important to predict invasive SDSE infection prognosis.

Indexed as

BiomarkersStreptococcal InfectionsStreptococcusAdultAgedAged, 80 and overAnti-Bacterial AgentsFemaleHumansMaleMiddle AgedRisk FactorsSeverity of Illness IndexYoung AdultAnti-Bacterial AgentsBiomarkersBiomarkeremm typeInvasive infectionRisk factor for deathStreptococcus dysgalactiae subsp. equisimilis

Identifiers

PMID38847928
PMCPMC11271329

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.